Nina Pauly1, Sarah Ehmann1, Enzo Ricciardi1, Beyhan Ataseven1,2, Mareike Bommert1, Florian Heitz1, Sonia Prader1, Stephanie Schneider1, Andreas du Bois1, Philipp Harter1, Thaïs Baert3,4. 1. Gynaecology and Gynaecological Oncology, Kliniken Essen-Mitte, Henricistraße 92, 45136, Essen, Germany. 2. Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany. 3. Gynaecology and Gynaecological Oncology, Kliniken Essen-Mitte, Henricistraße 92, 45136, Essen, Germany. thais.baert@gmail.com. 4. Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium. thais.baert@gmail.com.
Abstract
PURPOSE OF REVIEW: This review provides an overview of the current clinical standard in low-grade serous ovarian cancer (LGSOC). The available evidence for surgery and standard treatments is elaborated. In addition, we discuss recent findings and novel treatments for LGSOC. RECENT FINDINGS: Two large multicenter trials studying MEK inhibitors in LGSOC have been presented in the last year. Binimetinib demonstrated an activity in LGSOC, especially in KRAS-mutated disease. Trametinib was associated with an improved progression-free survival in relapsed LGSOC. Based on the current results, MEK inhibitors could be an alternative treatment for LGSOC. Surgery is an important step in the treatment of LGSOC. Hormonal therapy and bevacizumab can be beneficial, next to chemotherapy. Targeted treatments, such as the MEK-inhibitor trametinib, seem to be efficient and should be introduced into clinical practice.
PURPOSE OF REVIEW: This review provides an overview of the current clinical standard in low-grade serous ovarian cancer (LGSOC). The available evidence for surgery and standard treatments is elaborated. In addition, we discuss recent findings and novel treatments for LGSOC. RECENT FINDINGS: Two large multicenter trials studying MEK inhibitors in LGSOC have been presented in the last year. Binimetinib demonstrated an activity in LGSOC, especially in KRAS-mutated disease. Trametinib was associated with an improved progression-free survival in relapsed LGSOC. Based on the current results, MEK inhibitors could be an alternative treatment for LGSOC. Surgery is an important step in the treatment of LGSOC. Hormonal therapy and bevacizumab can be beneficial, next to chemotherapy. Targeted treatments, such as the MEK-inhibitor trametinib, seem to be efficient and should be introduced into clinical practice.
Entities:
Keywords:
Low-grade serous - rare tumor; MEK inhibitor; Ovarian cancer
Authors: David M Gershenson; Charlotte C Sun; Revathy B Iyer; Anais L Malpica; John J Kavanagh; Diane C Bodurka; Kathleen Schmeler; Michael Deavers Journal: Gynecol Oncol Date: 2012-03-06 Impact factor: 5.482
Authors: David M Gershenson; Charlotte C Sun; Karen H Lu; Robert L Coleman; Anil K Sood; Anais Malpica; Michael T Deavers; Elvio G Silva; Diane C Bodurka Journal: Obstet Gynecol Date: 2006-08 Impact factor: 7.661
Authors: N Colombo; C Sessa; A du Bois; J Ledermann; W G McCluggage; I McNeish; P Morice; S Pignata; I Ray-Coquard; I Vergote; T Baert; I Belaroussi; A Dashora; S Olbrecht; F Planchamp; D Querleu Journal: Ann Oncol Date: 2019-05-01 Impact factor: 32.976
Authors: Marta A Crispens; Diane Bodurka; Michael Deavers; Karen Lu; Elvio G Silva; David M Gershenson Journal: Obstet Gynecol Date: 2002-01 Impact factor: 7.661
Authors: Anais Malpica; Michael T Deavers; Karen Lu; Diane C Bodurka; Edward N Atkinson; David M Gershenson; Elvio G Silva Journal: Am J Surg Pathol Date: 2004-04 Impact factor: 6.394
Authors: Andreas du Bois; Nina Ewald-Riegler; Nikolaus de Gregorio; Alexander Reuss; Sven Mahner; Christina Fotopoulou; Friedrich Kommoss; Barbara Schmalfeldt; Felix Hilpert; Tanja Fehm; Alexander Burges; Werner Meier; Peter Hillemanns; Lars Hanker; Annette Hasenburg; Hans-Georg Strauss; Martin Hellriegel; Pauline Wimberger; Mignon-Denise Keyver-Paik; Klaus Baumann; Ulrich Canzler; Kerstin Wollschlaeger; Dirk Forner; Jacobus Pfisterer; Willibald Schröder; Karsten Münstedt; Barbara Richter; Stefan Kommoss; Steffen Hauptmann Journal: Eur J Cancer Date: 2013-03-13 Impact factor: 9.162
Authors: Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer Journal: Cancer Date: 2009-03-15 Impact factor: 6.860
Authors: Rachel N Grisham; Brooke E Sylvester; Helen Won; Gregory McDermott; Deborah DeLair; Ricardo Ramirez; Zhan Yao; Ronglai Shen; Fanny Dao; Faina Bogomolniy; Vicky Makker; Evis Sala; Tara E Soumerai; David M Hyman; Nicholas D Socci; Agnes Viale; David M Gershenson; John Farley; Douglas A Levine; Neal Rosen; Michael F Berger; David R Spriggs; Carol A Aghajanian; David B Solit; Gopa Iyer Journal: J Clin Oncol Date: 2015-08-31 Impact factor: 44.544
Authors: Lauren C Peres; Kara L Cushing-Haugen; Martin Köbel; Holly R Harris; Andrew Berchuck; Mary Anne Rossing; Joellen M Schildkraut; Jennifer A Doherty Journal: J Natl Cancer Inst Date: 2019-01-01 Impact factor: 13.506